Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Vical Inc. ($VICL) announced that the FDA has advised the company that a single successful Phase 2 clinical trial may be sufficient to support approval of antifungal VL-2397 under Limited Use Indication (LUI) status. The company plans to start its mid-stage study this quarter in acute leukemia and allogeneic hematopoietic cell transplant patients who have invasive aspergillosis. Vical had licensed VL-2397 from Astellas Pharma in 2015. VL-2397 is an isolate of a leaf litter fungus collected in Malaysia.
The stock responded positively to the news and jumped over 46 percent in its premarket session, trimming its 12 months losses to 15 percent.

Titan Pharmaceuticals ($TTNP) jumped on the news of its new collaboration with Opiant Pharmaceuticals. The deal pertains to the development of a subcutaneous implant to deliver therapeutic levels of an opioid antagonist to treat opioid use disorder. The implant will use Titan's ProNeura sustained-release technology and will be designed to deliver therapy for up to six months. The companies did not disclose the financial terms of the deal.
Titan Pharmaceuticals stock jumped over 5 percent in its previous trading session. The stock is currently down 53 percent on year to date basis while its 12 months loss stands at 68 percent.


Mallinckrodt ($MNK) announced is licensing deal with NeuroproteXeon for its investigational pharmaceutical-grade xenon gas for inhalation for the potential resuscitation of patients who have experienced cardiac arrest. The deal entails $10 million up front and up to $25M in milestones and tiered royalties on net sales.

Asterias Biotherapeutics ($AST) announced positive results from the Phase 1/2 SCiStar study assessing AST-OPC1 in patients with subacute motor complete spinal cord injury. The data at month 12 showed 67% of those with AIS-A-categorized injury receiving 10M AST-OPC1 cells (Cohort 2) recovered at least two motor levels on at least one side, more than double the rate seen historically with standard-of-care treatment.

Lannett Company ($LCI) reported that the FDA has approved its marketing applications for Lansoprazole Delayed-Release Capsules USP, 15 mg and 30 mg, its generic version of Takeda Pharmaceutical's Prevacid Delayed-Release Capsules, 15 mg and 30 mg and an over-the-counter 15 mg version, the generic equivalent to GlaxoSmithKline's Prevacid 24 HR Delayed-Release Capsules, 15 mg.

Alere ($ALR) announced receiving 510(k) clearance from the FDA for its i Influenza A& B 2 test for the detection of influenza A and B infection in children and adults. This test may provide results in as little as five minutes from nasal or nasopharyngeal swab specimens.


Boston Scientific ($BSX) announced inking a new agreement for acquiring Apama Medical. The deal entails upfront cash payment of $175 million. It will also involve up to $125 million in various milestones. Apama has developed a novel ablation catheter technology that is the basis for its Apama Radiofrequency Balloon Catheter System used to treat atrial fibrillation.

Merck ($MRK) reported signing a new deal with SELLAS Life Sciences Group for the evaluation of the combination of galinpepimut-S and Keytruda (pembrolizumab) in a range of cancers, including both blood cancers and solid tumors in a Phase 1/2 study.

Brokerage Action Company Rating Price Target Impact on Share Price Actions
Royal Bank Of Canada Reiterates Abbott Laboratories (ABT)
Buy $55.00 Low

Royal Bank Of Canada Reiterates Akorn (AKRX)
Hold $34.00 Low

Royal Bank Of Canada Reiterates Baxter International (BAX)
Hold $60.00 Low

Royal Bank Of Canada Reiterates Chemed Corp. (CHE)
Hold $209.00 Low

Royal Bank Of Canada Reiterates Endologix (ELGX)
Hold $5.00 Low

Gainers (% price change)Last TradeChangeMkt CapEndocyte, Inc.ECYT3.63+2.22 (157.45%)154.55MRigel PharmaceuticalsRIGL3.37+0.83 (32.68%)419.20MAcelRx PharmaceuticalsACRX5.50+0.90 (19.57%)249.59MSynergy PharmaceuticalsSGYP3.25+0.35 (12.07%)731.10MInsys Therapeutics IncINSY9.95+1.07 (12.05%)723.33MLosers (% price change)Rockwell Medical IncRMTI7.85-0.71 (-8.29%)406.16MCompugen Ltd. (USA)CGEN3.55-0.25 (-6.58%)178.64MDENTSPLY SIRONA IncXRAY56.33-3.48 (-5.82%)12.93BMomenta PharmaceuticalsMNTA17.95-0.55 (-2.97%)1.37BGTx, Inc.GTXI7.98-0.24 (-2.92%)128.15MMost Actives (dollar volume)Gilead Sciences, Inc.GILD83.52+2.50 (3.09%)109.07BCelgene CorporationCELG146.04+0.22 (0.15%)114.25BJohnson & JohnsonJNJ131.22+1.21 (0.93%)352.19BPfizer Inc.PFE36.07+0.37 (1.04%)214.80BRegeneron PharmaceuticalsREGN462.24+15.12 (3.38%)49.53B